Drug Trial Radar · NCT07687784
A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,366
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jun 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- AFT Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- HungaroTrial
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are: * Does hemoglobin increase by the same amount 6 weeks after each treatment? * What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric Bepectate to double dose treatment plans of both Ferric Bepectate and Ferric carboxymaltose. Participants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.
Conditions
- Iron Deficiency Anemia (IDA)
Interventions
Ferric Bepectate IV InjectionDrug
Ferric Bepectate IV Injection 50 mg iron/mL
Ferric Carboxymaltose Injection [Ferinject]Drug
Ferric carboxymaltose (Ferinject®) 50 mg iron/mL in two doses 7-9 days apart
Ferric Carboxymaltose Injection [Injectafer®]Drug
Ferric carboxymaltose (Injectafer®) 50 mg iron/mL in two doses 7-9 days apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in hemoglobin comparing one dose Ferric bepectate and two dose Injectafer treatmentTime frame: 6 weeks
- Change in hemoglobin comparing one dose Ferric bepectate and two dose Ferinject treatmentTime frame: 6 weeks
- Incidence of treatment emergent adverse eventsTime frame: 2 hours post infusion start
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Trialmed Phoenix
Phoenix, Arizona · Recruiting
PharmaSouth Research
Coral Gables, Florida · Recruiting
M3 Wake Research - Lake City
Lake City, Florida · Recruiting
Trialmed Melbourne
Melbourne, Florida · Recruiting
Trialmed The Villages
The Villages, Florida · Recruiting
Trialmed Evansville
Evansville, Indiana · Recruiting
Ingham Nephrology & Hypertension, P.C.
Lansing, Michigan · Recruiting
Brookhaven Heart
Patchogue, New York · Recruiting
Trialmed Asheboro
Asheboro, North Carolina · Recruiting
M3 Wake Research - Raleigh
Raleigh, North Carolina · Recruiting
M3 Wake Research - Charleston
Charleston, South Carolina · Recruiting
Trialmed Austin
Austin, Texas · Recruiting
M3 Wake Research
Dallas, Texas · Recruiting
PatientCare Clinical Research
Houston, Texas · Recruiting
Trialmed San Antonio
San Antonio, Texas · Recruiting
Medical Center Levitas EOOD
Sofia, Bulgaria · Not yet recruiting
Momentum West Auckland
Auckland, New Zealand · Not yet recruiting
Momentum Waikato
Hamilton, New Zealand · Not yet recruiting
Momentum Hutt Valley
Upper Hutt, New Zealand · Not yet recruiting
Szpital AidPort
Skórzewo, Poland · Not yet recruiting
Ames Medical Research
Bragadiru, Romania · Not yet recruiting
Colentina Clinical Hospital
Bucharest, Romania · Not yet recruiting
Sana Medical Center
Bucharest, Romania · Not yet recruiting
The Oncology Institute
Cluj-Napoca, Romania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.